ReWalk Robotics Ltd. Appoints Ori Gon as Chief Financial Officer
January 05 2018 - 4:30PM
ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq:RWLK)
today announced the Company has appointed its Corporate Controller,
Ori Gon as Chief Financial Officer (CFO), effective February 22,
2018, succeeding Kevin Hershberger, who has served as CFO since
2014. Mr. Hershberger is leaving to pursue an outside opportunity
after putting in place and executing on ReWalk’s business
strategies in collaboration with the Company’s board and management
team. Mr. Hershberger will work closely with Mr. Gon to ensure a
smooth and seamless transition.
“We are delighted to appoint Ori, who was originally hired and
groomed under Kevin’s leadership and guidance, as ReWalk’s new
CFO. Ori has a deep knowledge of our operating systems,
experience in managing liquidity, and familiarity with our markets,
making him uniquely qualified to continue to seamlessly drive our
financial strategy,” said ReWalk CEO Larry Jasinski.
Mr. Gon, 36, has served as a Corporate Controller of the Company
since July 2015. Previously, he served as Controller at On Track
Innovations, Ltd. from 2012 to 2015. He served as an Audit Manager
at KPMG from 2008 to 2012. Mr. Gon served as an officer in the
Israeli Defense Forces from 2000 to 2004 and is now a captain in
the military reserve. Mr. Gon is a CPA and holds a B.A. in
Economics from Hebrew University of Jerusalem.
“We thank Kevin for all of his many contributions to
ReWalk. Kevin has been an integral part and a valuable member
of ReWalk’s management team. Kevin was instrumental in establishing
a solid financial reporting and controls infrastructure and
building an experienced and knowledgeable finance team, following
ReWalk’s IPO. For the past three years, he has led strategic
funding and business planning efforts to prepare ReWalk for
long-term growth. We appreciate him staying on through the
transition, and wish him the best in his future endeavors,” added
Jasinski.
About ReWalk Robotics Ltd.ReWalk Robotics Ltd. develops,
manufactures and markets wearable robotic exoskeletons for
individuals with spinal cord injury. Our mission is to
fundamentally change the quality of life for individuals with lower
limb disability through the creation and development of market
leading robotic technologies. Founded in 2001, ReWalk has
headquarters in the U.S., Israel and Germany. For more information
on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in
Israel.
Forward-Looking StatementsIn addition to historical information,
this press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995, Section 27A of the U.S. Securities Act of 1933, and Section
21E of the U.S. Securities Exchange Act of 1934. Such
forward-looking statements may include projections regarding
ReWalk’s future performance and, in some cases, may be identified
by words like “anticipate,” “assume,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “future,” “will,” “should,”
“would,” “seek” and similar terms or phrases. The forward-looking
statements contained in this press release are based on
management’s current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk’s control.
Important factors that could cause ReWalk’s actual results to
differ materially from those indicated in the forward-looking
statements include, among others: ReWalk’s expectations regarding
future growth, including its ability to increase sales in its
existing geographic markets, expand to new markets and achieve its
planned expense reductions; the conclusion of ReWalk’s management
for the financial statements for the third quarter of 2017 and for
fiscal 2016, and the opinion of ReWalk’s auditors in their report
on the Company’s financial statements for fiscal 2016, that there
are substantial doubts as to ReWalk’s ability to continue as a
going concern; ReWalk’s ability to maintain and grow its reputation
and the market acceptance of its products; ReWalk’s ability to
achieve reimbursement from third-party payors for its products;
ReWalk’s expectations as to its clinical research program and
clinical results; ReWalk’s expectations as to the results of, and
the Food and Drug Administration’s potential regulatory
developments with respect to, ReWalk’s mandatory post-market 522
surveillance study; the outcome of ongoing shareholder class action
litigation relating to ReWalk’s initial public
offering; ReWalk’s ability to repay its secured indebtedness;
ReWalk’s ability to improve its products and develop new products;
ReWalk’s ability to maintain adequate protection of its
intellectual property and to avoid violation of the intellectual
property rights of others; ReWalk’s ability to gain and maintain
regulatory approvals; ReWalk’s ability to secure capital from its
equity and debt financings in light of limitations under its Form
S-3, the price range of its ordinary shares and conditions in the
financial markets, and the risk that such financings may dilute
ReWalk’s shareholders or restrict its business; ReWalk’s ability to
use effectively the proceeds of its offerings of its securities;
ReWalk’s ability to maintain relationships with existing customers
and develop relationships with new customers; the impact of the
market price of ReWalk’s ordinary shares on the determination of
whether ReWalk is a passive foreign investment company; ReWalk’s
ability to comply with the continued listing requirements of the
NASDAQ Capital Market and the risk that its ordinary shares will be
delisted if it cannot do so; ReWalk’s compliance with medical
device reporting regulations to report adverse events involving its
products and the potential impact of such adverse events on
ReWalk’s ability to market and sell its products; and other factors
discussed under the heading “Risk Factors” in ReWalk’s Annual
Report on Form 10-K for the year ended December 31,
2016, as amended, filed with the U.S. Securities and Exchange
Commission and other documents subsequently filed with or
furnished to the U.S. Securities and Exchange Commission. Any
forward-looking statement made in this press release speaks only as
of the date hereof. Factors or events that could cause ReWalk’s
actual results to differ from the statements contained herein may
emerge from time to time, and it is not possible for ReWalk to
predict all of them. Except as required by law, ReWalk undertakes
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
Investor Contact:Lisa M. WilsonPresidentIn-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Media Contact:Jennifer WlachT: 202-261-4000E:
media@rewalk.com
ReWalk Robotics (NASDAQ:RWLK)
Historical Stock Chart
From Aug 2024 to Sep 2024
ReWalk Robotics (NASDAQ:RWLK)
Historical Stock Chart
From Sep 2023 to Sep 2024